



CS/NSE/UFR/2011-12
May 4, 2012

TO
THE MANAGER
LISTING DEPARTMENT
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
EXCHANGE PLAZA, BANDRA KURLA COMPLEX
BANDRA (E), MUMBAI - 400 051

Dear Sir/Madam,

Stock Code - SUVEN-EQ

Sub: Notification of Un-audited Financial Results for the quarter ended 31/03/2012 -
Clause 41

.....
With reference to the above subject, we are forwarding here with Un-audited Financial Results of our Company for three months ended 31st March, 2012 in the prescribed proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Un-audited Financial Results for the 4th Quarter in its meeting held on 04th May, 2012.

Please find enclosed Press release of our company. We request you to take these Documents on your Records

Thanking You,

Yours faithfully,
For **SUVEN LIFE SCIENCES LIMITED**


K HANUMANTHA RAO
Company Secretary

Suven Life Sciences Limited

Regd. Office: Serene Chambers, Road # 5, Avenue 7, Banjara Hills, Hyderabad 500 034, INDIA

Tel: 91~40~2354 1142/ 3311, 3292 1695/ 96, Fax: 91~40~2354 1152

info@suven.com

www.suven.com

SUVEN Life Sciences



News Release

Suven's PAT up by 137% for 4th Quarter ended 31st Mar'2012

HYDERABAD, INDIA (4 May 2012) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its un-audited financial results for the quarter ended 31st Mar 2012. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 4th May, 2012 at Hyderabad.

Financial Highlights for the 4th Quarter ended March 2012:

Growth in revenue	Rs 624 mil vs. Rs 465 mil	- Up by 34.30%
Growth in PAT	Rs 83 mil vs. Rs 35 mil	- Up by 137.26%
Growth in EBITDA	Rs 130.23 mil vs. Rs 56.61 mil	- Up by 130.07%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 84.5 mil (13.54% on revenue) for the quarter ended Mar' 2012.

12 months period ended 31st Mar, 2012, recorded a revenue growth of 35.63%, increase in PAT by 49.26% and increase in EBITDA by 70.272%. Total R&D expenditure for the year ended Mar' 2012 stood at Rs. 332.82 mil (previous period Rs. 311.43 mil).


*PAT for the year ending Mar 2012 is after provision for MTM of Rs. 34.80 mil towards forward contracts due to exchange fluctuation

During the quarter there were major qualitative achievements with the grant of 3 product patents to Suven's drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;



Going beyond Commitment.



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st MARCH 2012

PART - I

Sl. No.	PARTICULARS	Quarter Ended			Year Ended	Rs. In lacs
		31/3/2012	31/12/2011	31/03/2011	31/03/2012	Previous Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operations					
	(a) Net sales/income from operations (Net of excise duty)	6,251.37	4,863.70	4,564.62	20,382.73	15,043.38
	(b) Other operating income	-	-	-	-	-
	Total income from operations (net)	6,251.37	4,863.70	4,564.62	20,382.73	15,043.38
2	Expenses					
	a) Cost of materials consumed	2,464.72	2,125.68	1,846.29	8,123.06	5,549.85
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	445.86	(879.48)	(29.33)	(536.97)	(53.43)
	d) Employee benefits expense	503.54	583.66	532.31	2,152.88	1,782.08
	e) Depreciation and amortisation expense	137.29	138.27	136.16	554.29	544.55
	f) Other expenses - Manufacturing Exps	755.36	736.75	609.70	2,631.88	2,082.72
	- Selling Exps	43.19	41.64	121.74	216.24	261.95
	- Administrative Exps	745.87	664.11	233.92	1,789.56	951.09
	- R & D Exps	845.13	858.01	766.74	3,328.27	3,114.35
	- Provision for MTM on Forward Contracts	(854.63)	660.83	-	348.06	-
	Total expenses	5,086.33	4,929.47	4,217.53	18,607.27	14,233.16
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	1,165.04	(65.77)	347.09	1,775.46	810.22
4	Other Income	-	156.28	82.82	191.06	125.74
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	1,165.04	90.51	429.91	1,966.52	935.96
6	Finance costs	262.79	228.63	168.62	899.57	610.52
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	902.25	(138.12)	261.29	1,066.95	325.44
8	Exceptional Items	-	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7 ± 8)	902.25	(138.12)	261.29	1,066.95	325.44
10	Tax Expenses	71.70	(267.57)	(88.77)	(485.27)	(714.50)
11	Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10)	830.55	129.45	350.06	1,552.22	1,039.94
12	Extraordinary Items (net of tax expense) _____ Lakhs	-	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11 ± 12)	830.55	129.45	350.06	1,552.22	1,039.94
14	Share of profit / (loss) of associates*	-	-	-	-	-
15	Minority Interest *	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *	-	-	-	-	-
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	1,167.32	1,167.32	1,167.32	1,167.32	1,167.32
		Rs.1.00	Rs.1.00	Rs.1.00	Rs.1.00	Rs.1.00
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-
19.i	Earning Per Share (EPS) (before extraordinary items) (of ` Rs.1/- each) (not annualised):					
	a) Basic	0.71	0.11	0.30	1.33	0.89
	b) Diluted	0.71	0.11	0.30	1.33	0.89
19.ii	Earning Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):					
	a) Basic	0.71	0.11	0.30	1.33	0.89
	b) Diluted	0.71	0.11	0.30	1.33	0.89

* Applicable in the case of consolidated results



PART - II

A	PARTICULARS OF SHAREHOLDING	31/3/2012	31/12/2011	31/03/2011	31/03/2012	31/3/2011
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Public share holdings					
	- Number of shares	42,679,160	42,679,160	42,858,960	42,679,160	42,858,960
	- Percentage of Share holding	36.56%	35.56%	36.72%	36.56%	36.72%
2	Promoters and promoter group Shareholding**					
a)	Pledged / Encumbered					
	- Number of shares	NIL	NIL	NIL	NIL	NIL
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL
b)	Non-Encumbered					
	- Number of shares	74,052,828	74,052,828	73,873,028	74,052,828	73,873,028
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	63.44%	63.44%	63.28%	63.44%	63.28%
	Particulars	3 months ended (31/03/2012)				
B	INVESTOR COMPLAINTS	0				
	Pending at the beginning of the quarter	24				
	Received during the quarter	24				
	Disposed of during the quarter	0				
	Remaining unresolved at the end of the quarter					

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED

PARTICULARS	Quarter Ended			Rs. In Lacs	
	31/3/2012	31/12/2011	31/03/2011	Year Ended	Year Ended
	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	SEGMENT REVENUE :-				
a)	Manufacturing (GRAMS)	5,921.55	4,592.12	3,965.17	19,168.88
b)	Services (DDSS)	329.82	271.58	599.45	1,213.85
c)	Research & Development	-	-	-	-
	Net Sales from Operations	6,251.37	4,863.70	4,564.62	20,382.73
2	SEGMENT RESULTS :-				
	Profit/(Loss) before tax and interest:				
a)	Manufacturing (GRAMS)	1,661.34	1,959.14	1,089.22	6,460.38
b)	Services (DDSS)	175.14	111.12	192.58	634.59
c)	Research & Development	(845.13)	(858.01)	(766.74)	(3,328.27)
	TOTAL	991.35	1,212.25	515.06	3,766.70
Less:	i) Interest	228.51	213.52	142.76	798.58
	ii) Other Un-allocable exps net off un-allocable income	(139.42)	1,136.85	111.01	1,901.17
	Total Profit Before Tax	902.26	(138.12)	261.29	1,066.95
3	CAPITAL EMPLOYED				
	(Segment Assets - Segment Liabilities)				
a)	Manufacturing (GRAMS)	16,108.38	14,356.18	12,075.70	16,108.38
b)	Services (DDSS)	428.88	312.27	629.97	428.88
c)	Research & Development	3,776.35	2,973.76	3,506.95	3,776.35
d)	Net assets which are not segmented and used commonly	7,282.79	4,103.06	3,036.80	7,282.79
	TOTAL	27,596.40	21,745.27	19,249.42	27,596.40

- Notes: 1) The above un-audited results were approved and taken on record at the Board of Directors' meeting held on 4th May'12
2) Previous years figures have been regrouped / reclassified whenever necessary.
3) The Limited review has been completed by the Statutory Auditors.
4) Provision for MTM Losses pertain to Forward Contracts entered for covering the future liabilities in USD.



For SUVEN LIFE SCIENCES LTD

VENKAT JASTI
Chairman & CEOPlace : Hyderabad
Date : 4th May'2012



SUVEN LIFE SCIENCES LTD

3d. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Statement of Assets & Liabilities as per Clause 41(V)(h) as per Listing agreement

(Rs. In lacs)

	Particulars	Half year Ended	
		3/31/2012	3/31/2011
A	EQUITY AND LIABILITIES		
1	Shareholder's funds:		
	(a) Share Capital	1,167.32	1,167.32
	(b) Reserves and Surplus	13,058.61	11,506.42
	(c) Money received against share warrants		
	Sub-total - Shareholders' funds	14,225.93	12,673.74
2	Share application money pending allotment	-	-
3	Minority interest *	-	-
4	Non-current liabilities:		
	(a) Long-term borrowings	4,404.66	4,074.58
	(b) Deferred tax liabilities (net)	-	-
	(c) Other long-term liabilities	-	-
	(d) Long-term provisions	136.35	104.08
	Sub-total - Non-current liabilities	4,541.01	4,178.66
5	Current liabilities:		
	(a) Short-term borrowings	3,440.43	2,501.10
	(b) Trade payables	2,437.54	1,892.45
	(c) Other current liabilities	2,059.07	519.64
	(d) Short-term provisions	892.43	597.79
	Sub-total - Current liabilities	8,829.47	5,510.98
	TOTAL - EQUITY AND LIABILITIES	27,596.41	22,363.38
B	ASSETS		
1	Non-current assets:		
	(a) Fixed assets	12,445.18	10,567.77
	(b) Goodwill on consolidation *	-	-
	(c) Non-current investments	3,043.04	1,073.61
	(d) Deferred tax assets (net)	1,251.87	766.59
	(e) Long-term loans and advances	2,016.13	1,249.26
	(f) Other non-current assets	182.46	168.43
	Sub-total - Non-current assets	18,938.68	13,825.66
2	Current assets:		
	(a) Current investments	447.33	965.42
	(b) Inventories	4,477.69	3,336.56
	(c) Trade receivables	2,483.65	3,137.38
	(d) Cash and cash equivalents	313.94	294.63
	(e) Short-term loans and advances	925.25	793.98
	(f) Other current assets	9.87	9.75
	Sub-total - Current assets	8,657.73	8,537.72
	TOTAL - ASSETS	27,596.41	22,363.38

* Applicable in the case of consolidated statement of assets and liabilities.

For Suven Life Sciences Ltd



Venkat Jasti
Venkat Jasti
Chairman & CEO